Clinical stage biopharmaceutical company Patrys Limited (ASX: PAB) has been granted a New Zealand patent for the anti-cancer product PAT-LM1, which is for the treatment or prevention of metastasis.
The patent is owned by Patrys, and claims the use of the antibody PAT-LM1 that binds to its target Nmt55/NONO. PAT-LM1 is currently under preclinical development.
The New Zealand Patent Office has issued a certificate of grant on a key patent in the PAT-LM1 family, PCT/IB2009/007082 entitled “LM-antibodies, functional fragments, LM-1 target antigen, and methods for making and using same”.
This is the second jurisdiction in which the PAT-LM1 patent has been granted.
Patrys currently has a pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities.
Patrys had around $5.8 million in cash at the end of March 2013.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.